Get Through ObamaCare Pain

Get Through ObamaCare Pain

Yesterday, in case you were unaware, was big day for politics with the government shut-down and the kick-off of Obamacare. As expected, there were ‘glitches’ in the system as wait times and hold times approached unbearable levels. Get used to it.

On Monday we stated that technology and healthcare were places to put some cash, particularly in stocks that have not run yet in 2013. Right on cue, the S&P Select Biotechnology Index (^SPISBI) was up over 2% and the iShares U.S. Technology ETF (IYW) was up 1.5%. Additionally, our new Market Monitor pick, TTM Technologies (NASDAQ – TTMI - $9.74), was up 1.75%.

Today we will shift gears to healthcare. Most analysts concur that Obamacare will actually help health insurance companies and several sectors of the healthcare industry. As it stands the medical device tax that is part of the law could devastate those related companies.

Pain Therapeutics, Inc. (NASDAQ – PTIE - $3.00) is a biotech firm that has been on an up and down ride in 2013. Back in May the stock was leveled with nearly a 50% drop in one trading session when its partner for the Company’s lead brand REMOXY painkiller, Pfizer (NYSE-PFE) was reviewing the program and considering abandoning it. In August Pfizer re-started a new study for the lead drug, which put PTIE back in the accumulation phase, part one of our 2013 4Q formula.

The new study for REMOXY is expected to be complete by the end of this month, with approval to follow.  This should keep Pain Therapeutics on track for profitability from an EPS perspective in 2014 as forecast; which is part two of our winning formula for the rest of 2013. FY P/E is a low 13 based on 2014 EPS estimates. Technical analysis is bullish in the shorter term DMA and very bullish in the long term (50-day) DMA.

PTIE has real potential to take off as REMOXY gets closer to market release. $5 by the end of 4Q13 is a level which should be reached.

Have a great day!

Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours.

Disclaimer:

This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. 

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations. 

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com